# Tumour mutational burden using a targeted panel approach for comprehensive tumour profiling focusing on colorectal cancer

## TL;DR

This paper reviews how measuring tumor mutations can help predict cancer treatment success and improve patient outcomes, with a focus on colorectal cancer.

## Contribution

The paper introduces a targeted panel approach for assessing tumor mutational burden and highlights its potential in guiding cancer treatment decisions.

## Key findings

- Tumor mutational burden assessment can predict immune checkpoint inhibitor success.
- Targeted therapies can be matched to specific tumor mutations identified through profiling.
- Colorectal cancer studies reveal gaps in understanding tumor development.

## Abstract

There is an increasing recognition that comprehensive tumour profiling (CTP) represents an important adjunct to the diagnosis of malignancy providing not only an assessment of how many mutations there are in any given tumour which reflects the probability of immune checkpoint inhibitor success, but also which mutations are associated with targeted therapies, a signature that reflects environmental insult and potentially the identification of cancers of unknown origin.

This short review describes an approach to assaying tumour mutational burden (TMB), what the difficulties are in the assessment of the TMB and what it can be applied to in regards to improving patient outcomes. A final section of the review delves into some examples of colorectal cancer studies that identify findings that suggest there remains much to learn about tumour development.